Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 9, 1439 (2003)
doi:10.1038/nm1203-1439
Erythropoietin may impair, not improve, cancer survival
Vicki Brower1
- New York
Erythropoietin (EPO), a drug commonly given to cancer patients to alleviate fatigue, may shorten survival in cancer patients and might in fact fuel tumor growth, a growing body of evidence suggests. Results from two clinical trials and various other studies could radically transform the current practice of prescribing the blockbuster drug for cancer-related anemia.
To read this story in full you will need to login or make a payment (see right).
